EC grants CMA to Janssen's Talvey for multiple myeloma

The European Commission (EC) has granted conditional marketing authorisation (CMA) to the Janssen Pharmaceutical Companies of Johnson & Johnson’s Talvey.

Related Keywords

Peter Lebowitz ,Drug Administration ,Janssen Research Development Oncology ,Development Oncology ,